Kanaph Therapeutics
Developing next generation therapeutics for oncology and autoimmune diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD130—195m (Dealroom.co estimates Dec 2023.)
Company register number 6438701092
South Korea (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.0m | Angel | |
$6.0m | Series A | ||
$21.0m | Series B | ||
N/A | $23.8m | Series B | |
Total Funding | CAD72.1m |